Neutralizing antibodies against EBV gp42 show potent in vivo protection and define novel epitopes

Author:

Wu Qian1,Zhong Ling23,Wei Dongmei1,Zhang Wanlin3,Hong Junping1,Kang Yinfeng3,Chen Kaiyun1,Huang Yang1,Zheng Qingbing1,Xu Miao3,Zeng Mu-Sheng3,Zeng Yi-Xin3,Xia Ningshao1ORCID,Zhao Qinjian2,Krummenacher Claude4,Chen Yixin1,Zhang Xiao2

Affiliation:

1. State Key Laboratory of Vaccines for Infectious Diseases, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, National Innovation Platform for Industry-Education Integration in Vaccine Research, School of Life Sciences, School of Public Health, Xiang An Biomedicine Laboratory, Xiamen University, Xiamen, People’s Republic of China

2. College of Pharmacy, Chongqing Medical University, Chongqing, People’s Republic of China

3. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, People’s Republic of China

4. Department of Biological and Biomedical Sciences, Rowan University, Glassboro, NJ, USA

Funder

National Natural Science Foundation of China

Natural Science Foundation of Chongqing

Natural Science Foundation of Fujian

Publisher

Informa UK Limited

Subject

Virology,Infectious Diseases,Drug Discovery,General Medicine,Immunology,Microbiology,Parasitology,Epidemiology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3